369 related articles for article (PubMed ID: 34174983)
1. First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
Cherng HJ; Jain N
Hematol Oncol Clin North Am; 2021 Aug; 35(4):725-738. PubMed ID: 34174983
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
3. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
4. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
5. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
6. Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
Lipsky AH; Lamanna N
Cancer; 2023 Jan; 129(1):18-31. PubMed ID: 36326285
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
Muhowski EM; Ravikrishnan J; Gordon B; Yu L; Misra S; Walker B; Eathiraj S; Sampath D; Rogers KA; Byrd JC; Woyach JA
J Hematol Oncol; 2022 Nov; 15(1):166. PubMed ID: 36380319
[TBL] [Abstract][Full Text] [Related]
8. Current Perspectives on Therapy for Chronic Lymphocytic Leukemia.
Awan FT; Al-Sawaf O; Fischer K; Woyach JA
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-10. PubMed ID: 32239979
[TBL] [Abstract][Full Text] [Related]
9. Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.
Roeker LE; Thompson M; Mato AR
Drugs; 2022 Feb; 82(2):133-143. PubMed ID: 34932207
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
Timofeeva N; Gandhi V
Blood Cancer J; 2021 Apr; 11(4):79. PubMed ID: 33927183
[TBL] [Abstract][Full Text] [Related]
11. Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm.
Scheffold A; Stilgenbauer S
Curr Oncol Rep; 2020 Feb; 22(2):16. PubMed ID: 32025827
[TBL] [Abstract][Full Text] [Related]
12. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
[TBL] [Abstract][Full Text] [Related]
13. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Miao Y; Xu W; Li J
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
[TBL] [Abstract][Full Text] [Related]
14. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
15. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
16. Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.
Banerji V; Aw A; Robinson S; Doucette S; Christofides A; Sehn LH
Curr Oncol; 2020 Dec; 27(6):e645-e655. PubMed ID: 33380880
[TBL] [Abstract][Full Text] [Related]
17. US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.
Kim MS; Prasad V
Cancer; 2020 Oct; 126(19):4270-4272. PubMed ID: 32644193
[TBL] [Abstract][Full Text] [Related]
18. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
Islam P
Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
Hanna KS; Fijalka A; Watson I; Brown O; Ojulu A
J Oncol Pharm Pract; 2022 Dec; 28(8):1869-1884. PubMed ID: 35635742
[TBL] [Abstract][Full Text] [Related]
20. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
